Advancing Cancer Treatment: The Contributions of Dr Erik Goluboff

Dr Erik Goluboff is a renowned physician, researcher, and leader in the field of urologic cancers. He has worked in this field since the early 1990s andheld various high-ranking positions at notable organizations. Presently, Dr Erik Goluboff is the Principal Medical Lead of Genentech’s drug development program in urologic cancers.
Dr Erik Goluboff initially graduated with his Doctor of Medicine (MD) degree from the University of Maryland School of Medicine in 1991. After completing his residency at the University of Pittsburgh Medical Center, he was accepted as a Fellow at the National Cancer Institute (NCI), located within the National Institutes of Health (NIH). While at the NCI, Dr Erik Goluboff was highly involved in research and clinical trials related to bladder cancer, prostate cancer, and other urologic cancers.
In 2000, Dr Erik Goluboff joined Memorial Sloan-Kettering Cancer Center as the Director of Genitourinary Oncology Clinical Trials. Throughout his time at Memorial Sloan-Kettering, he was responsible for designing and leading numerous clinical trials for various urologic cancers. He was also heavily involved in the development of new treatments and therapies, as well as the evaluation of existing treatments.
From 2004 to 2008, Dr Erik Goluboff served as the Chief Medical Officer of Urologix, a medical device company focused on treating urinary conditions. During this time, he contributed to developing several urologic devices, including those used to treat bladder and prostate cancer.
In 2008, Dr Erik Goluboff was appointed as a Professor of Urology and Oncology at the University of Pennsylvania. During this time, he was heavily involved in research and clinical trials related to urologic cancers. He also served as the Associate Director of the University of Pennsylvania’s Genitourinary Program.
In 2014, Dr Erik Goluboff joined Genentech as the Principal Medical Lead for their drug development program in urologic cancers. At Genentech, he oversees the development and clinical trial programs for new and existing urologic cancers and the evaluation of existing treatments. Additionally, Dr Erik Goluboff has been an integral part of developing several drugs and vaccines and is responsible for evaluating their efficacy and safety.